Bristol
NHS Blood and Transplant Gene Therapy Hub
The NHSBT Gene Therapy Hub is part of the Clinical Biotechnology Centre (CBC). The CBC has been manufacturing GMP-grade DNA plasmids for over 20 years, and brings their wealth of expertise and experience transferring manufacturing processes to GMP compliance to the Innovation Hubs network. The NHSBT Gene Therapy Hub is hosted within a purpose built 1,000m2 facility for the production of gene therapies under GMP. The facility was funded jointly by NHSBT and the Department of Health and Social Care and is based at the NHSBT Filton Blood Centre (Bristol).
The Hub supports both early phase academic-led and commercial gene therapy trials, and facilitates the provision of cost-effective viral vectors and plasmid DNA to stimulate the UK’s gene therapy sector.
The CBC is led by Dr Jon Smythe and Dr Paul Lloyd-Evans, and provides viral vector manufacturing, training and support services for academic-led groups seeking Adeno Associated Viral (AAV), Lentiviral (LV) vectors and plasmid DNA at GMP and research-grade qualities.
NHSBT also supports academic-led teams in the translation of their research to the clinic and works with the other Hubs to develop, optimise and deliver a comprehensive training package. CBC is committed to generating a highly skilled workforce, serving both the academic and commercial gene therapy communities.
The CBC operates as part of the Cellular and Molecular Therapies (CMT) function within NHSBT. Other services provided by CMT include the development and manufacture of advanced cell therapies under GMP.
To find out more
- Click here to visit our NHSBT website
- Follow us on LinkedIn & Twitter
People
- Director: Dr Jon Smythe
- Co-Director: Dr Paul Lloyd-Evans
- Viral Vector Hub Manager: Dr Sujith Sebastian
- Project Manager: Charlotte McHugh
- Skills and Training Lead: Dr Suhair Salman
- Manufacturing Science And Technologies Lead: Dr Piers Walser
- Business Development Manager, Clinical Biotechnology Centre: Hollie Yaxley
- Head of Business Development, Cellular & Molecular Therapies: Teresina Pinnington
